Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75643

UPID:
U520_HUMAN

ALTERNATIVE NAMES:
Activating signal cointegrator 1 complex subunit 3-like 1; BRR2 homolog; U5 snRNP-specific 200 kDa protein

ALTERNATIVE UPACC:
O75643; O94884; Q6NZY0; Q6PX59; Q8NBE6; Q96IF2; Q9H7S0

BACKGROUND:
U5 small nuclear ribonucleoprotein 200 kDa helicase, known alternatively as Activating signal cointegrator 1 complex subunit 3-like 1, BRR2 homolog, and U5 snRNP-specific 200 kDa protein, is integral to the splicing of U12-type introns in pre-mRNAs. It mediates essential steps in spliceosome assembly, activation, and disassembly, facilitating the ATP-dependent unwinding of U4/U6 RNA duplexes.

THERAPEUTIC SIGNIFICANCE:
The involvement of U5 small nuclear ribonucleoprotein 200 kDa helicase in Retinitis pigmentosa 33 highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies, particularly in the realm of pigmentary retinopathies, by modulating spliceosome activity.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.